Gilead Sciences Competitive Intelligence & Landscape

Gilead Sciences focuses on three primary therapeutic areas: virology, oncology, and inflammation [https://www.gilead.com/company]. Within virology, their efforts include HIV, viral hepatitis, and neglected & emerging viruses and pandemic preparedness. In oncology, they are actively developing treatments, including a newly approved first-line treatment for metastatic triple-negative breast cancer [https://gilead.com/]. The company also addresses serious respiratory and cardiovascular conditions [https://www.gilead.com/~/media/Files/pdfs/other/Gilead%20Sciences%20Company%20Overview%20%20US%2081913.pdf].

Founded almost 40 years ago [https://investors.gilead.com/overview/default.aspx], Gilead Sciences has its worldwide corporate headquarters in Foster City, California, specifically at 333 Lakeside Drive, Foster City, CA 94404 [https://www.gilead.com/company/us-locations]. The company operates in more than 35 countries, aiming to improve health outcomes and reimagine care globally [https://www.gilead.com/company].

The leadership team, guided by Chairman and Chief Executive Officer Daniel O'Day, provides guidance to execute their mission and realize their vision of creating a healthier world for all people [https://www.gilead.com/company/leadership].

Gilead Sciences continues to drive innovation through bold and transformative science, striving to develop the next generation of life-changing medicines [https://investors.gilead.com/overview/default.aspx].

One significant program is Gilead’s Advancing Access program, which assists eligible individuals with information regarding insurance and financial support, including co-pay assistance for HIV treatment and prevention medications [https://www.gilead.com/medicines/medication-access/us-patient-access]. Historically, Gilead has also provided HIV treatment and prevention medicines, as well as chronic hepatitis B virus (HBV) medicines, free of charge to eligible uninsured individuals in the U.S. through the Advancing Access Patient Assistance/Medication Assistance Program (PAP/MAP) [https://www.gilead.com/company/company-statements/2021/gilead-announces-updates--to-the-advancing--access-patient-assistancemedication-assistance-program].

For healthcare providers, Gilead offers Managed Access programs, such as compassionate use, for investigational medicines outside of clinical trials when no other satisfactory treatment options are available for serious or life-threatening conditions [https://www.gilead.com/medicines/medication-access/managed-access]. In a strategic move to lower costs for Americans, Gilead announced an agreement with the U.S. government to implement a new pricing strategy, which includes discounts on certain existing medicines [https://www.gilead.com/news/news-details/2025/gilead-and-u-s--government-enter-agreement-to-lower-costs-of-medicines-for-americans].

Furthermore, Gilead actively works on global health and access initiatives, particularly in low- and middle-income countries, to ensure access to life-changing medications. For example, they have developed a voluntary licensing strategy for lenacapavir for HIV prevention to enable access in high-incidence, resource-limited countries and are pursuing a bridging strategy for direct provision of long-acting PrEP until generic supply is available [https://www.gilead.com/company/company-statements/2025/gilead-statement-on-access-planning-for-lenacapavir-for-hiv-prevention-in-low--and-middle-income-countries, https://www.gilead.com/responsibility/global-health-and-access/access-in-low--and-middle-income-countries/access-strategy-for-long-acting-prep]. While specific consumer pricing plans are not directly offered, Gilead emphasizes patient support and global accessibility for its therapies.

A significant focus for Gilead Sciences recruitment efforts is within its Research teams. These roles are critical for generating new medicines and cures, aligning with the company's robust and diverse pipeline of therapies. This sustained emphasis on research roles indicates a strategic investment in innovation and the development of new treatments [https://www.gilead.com/careers/opportunities].

Gilead Sciences also prioritizes early career opportunities, including dedicated internship programs and postdoctoral fellowships [https://www.gilead.com/careers/opportunities/early-career-opportunities]. These programs are designed to nurture emerging talent and support long-term growth within the scientific and pharmaceutical fields, signaling a commitment to developing future leaders and specialists.

While specific layoff announcements are not prominently featured on the official Gilead Sciences career pages, the company's consistent advertising of numerous job openings across various therapeutic areas, including Virology and Oncology, suggests a pattern of growth and strategic hiring to support its expanding portfolio and pipeline [https://www.gilead.com/careers/opportunities][https://gilead.com/]. This proactive recruitment across different experience levels, from early career to experienced professionals, reflects a strong focus on scientific advancement and market expansion.

Gilead Sciences continues to show financial resilience, with first-quarter 2026 total revenues of $6.8 billion and product sales excluding Veklury growing 8% year-over-year [https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-Announces-First-Quarter-Financial-Results/default.aspx]. The company's financial health is further supported by its robust cash position, holding $9.4 billion in cash, cash equivalents, and marketable debt securities as of September 30, 2025, and generating $4.1 billion in operating cash flow during the third quarter of 2025 [https://investors.gilead.com/files/doc%5Ffinancials/2025/q3/GILD-Q325-Earnings-Press-Release-30-October-2025.pdf].

In terms of fundraising, Gilead Sciences announced the pricing of $3 billion of senior unsecured notes in an underwritten, registered public offering. This issuance included $500 million of 4.250% senior notes maturing in 2028, $1 billion of 4.400% senior notes maturing in 2029, and $1 billion of 4.600% senior notes. This strategic move highlights the company's ability to secure significant capital to support its operations and ongoing research and development initiatives [https://www.gilead.com/news/news-details/2026/gilead-prices-3-billion-of-senior-unsecured-notes]. The company actively funds research through various programs, including external-sponsored research and community-based participatory research [https://www.gilead.com/science/research/research-funding-programs].

In the second quarter of 2026, Gilead Sciences executives are scheduled to speak at several investor conferences. These include the BofA Securities Health Care Conference on May 12, 2026, and the RBC Capital Markets Global Healthcare Conference on May 19, 2026 [www.gilead.com/news/news-details/2026/gilead-sciences-to-present-at-upcoming-second-quarter-2026-investor-conferences].

Looking back at past engagements, Gilead Sciences has been a consistent presence at major healthcare and strategic decision conferences. Archived events include presentations at the Barclays Annual Global Healthcare Conference on March 11, 2026, and the TD Cowen Annual Health Care Conference on March 3, 2026 [investors.gilead.com/events-and-presentations/events/event-details/2026/Barclays-Annual-Global-Healthcare-Conference-2026-1ghvW6YNHw/default.aspx].

Other notable participations in 2026 include the Bernstein’s Annual Strategic Decisions Conference on May 28, 2026, and the RBC Capital Markets Global Healthcare Conference on May 19, 2026 [investors.gilead.com/events-and-presentations/events/event-details/2026/Bernsteins-Annual-Strategic-Decisions-Conference-2026-V189S4fPJ_/default.aspx]. These events provide platforms for Gilead Sciences to communicate with the investment community.